Table 3

Number of breast cancer cases and controls, and ORsa associated with CYP17 polymorphism by menopausal status and tumor stage

A1/A1A1/A2A2/A2A1/A2 and A2/A2
Premenopausal
Controls, n (%)88 (43.3)88 (43.3)27 (13.3)115 (56.7)
Cases by stage
Local, n (%)42 (43.8)44 (45.8)10 (10.4)54 (56.2)
OR (95% CI)1.0b1.02 (0.59–1.76)0.73 (0.31–1.72)c0.95 (0.56–1.60)
Advanced, n (%)35 (52.2)27 (40.3)5 (7.5)32 (47.8)
OR (95% CI)1.0b0.62 (0.32–1.20)0.43 (0.14–1.27)d0.58 (0.31–1.07)
Postmenopausal
Controls, n (%)112 (40.4)132 (47.7)33 (11.9)165 (59.6)
Cases by stagee
Local, n (%)78 (40.2)90 (46.4)26 (13.4)116 (59.8)
OR (95% CI)1.0b1.02 (0.65–1.60)1.09 (0.55–2.16)f1.03 (0.67–1.59)
Advanced, n (%)39 (34.8)63 (56.3)10 (8.9)73 (65.2)
OR (95% CI)1.0b1.02 (0.58–1.79)0.86 (0.34–2.18)g0.99 (0.57–1.69)
  • a Adjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign breast disease, use of oral contraceptives, WHR, and postmenopausal use of estrogen.

  • b Subjects with A1/A1 genotype serve as the reference category.

  • c P for trend = 0.593.

  • d P for trend = 0.059.

  • e Total number does not correspond because the stage of the disease could not be classified for 10 patients because of missing information on lymph node involvement.

  • f P for trend = 0.830.

  • g P for trend = 0.832.